OWC Pharmaceutical Research Corp (OWCP)

[GP65]

News: OWCP to meet with investors, researchers, and business partners at the 2018 MJBizCon November 14-16 revealing the testing of novel formulation for multiple myeloma therapy. https://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-to-meet-with-investors-researchers-and-business-partners-at-2018-mjbizcon-revealing-the-testing-of-novel-formulation-for-multiple-myeloma-therapy-300744688.html

During MJBizCon the company's management will hold meetings with investors, researchers and business partners as part of the company's on-going product commercialization efforts in north America.

With regards to the successful tests of its innovative delivery formulation aimed at Multiple Myeloma therapy. This newly developed, highly concentrated, formulation, OWC-1808, was administered in vivo in an animal model for the first time and was found to be safe and tolerable. This breakthrough formulation will allow the delivery of very high doses of CBD and THC with exceptional bioavailability.

Dr. Stanley Hirsch, the Chairman of OWCP said: "This is an important milestone in our pre-clinical development of cannabis-based therapies for Multiple Myeloma. This incurable blood cancer effects about 30,000 new patients a year in the USA alone. Cannabis-based therapies represent a new frontier in fighting this disease and this potentially moves cannabis from being a cancer palliative to becoming a cancer therapeutic."